The colonoscopic polypectomy is at the forefront in reducing the incidence of colorectal cancer. However, the endoscopic polypectomy has been reported to be accompanied by risks of complications. Postpolypectomy bleeding (PPB) is the most common complication, with an incidence ranging from 0.6% to 8% in large series [1] [2] [3] . The incidence of PPB has been reported to depend on its definition: early, delayed, and overall [4] .
Many factors are associated with an increased risk for PPB and can be categorized into patient-, polyp-, and procedure-related factors. Patient-related factors include the use of an anticoagulant agent and various host comorbidities such as hypertension, severe pulmonary disease, and chronic renal failure. Recently, as more individuals are taking anticoagulant or antiplatelet agents such as warfarin, clopidogrel, aspirin, and nonsteroidal anti-inflammatory drugs, preventing PPB in these patients has become one of challenging issues in a colonoscopic polypectomy. A large retrospective cohort study reported warfarin therapy to be an independent predictor of PPB (adjusted odds ratio, 11.6; 95% confidence interval, 2.3-57.3) and suggested that additional methods to reduce the likelihood of PPB in anticoagulated patients should be investigated [5] . However, warfarin interruption for a colonoscopy also has an increased risk of a thromboembolic event. Garcia et al. [6] reported thromboembolic events in 0.7% of 1,293 patients with warfarin interruptions, and Blacker et al. [7] reported that strokes occurred in 1% of 987 patients with atrial fibrillation after temporary anticoagulation discontinuation. Until now,
